Q&A
Exclusive interviews with industry leaders
-
Permission granted by Argenx
A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
Meagan Parrish • Aug. 28, 2026 -
Getty Images
Is AI finally proving its worth in drug R&D?
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?
Kelly Bilodeau • Aug. 26, 2026 -
Getty Images
Legend’s interim CEO sees a shorter path to the next era of CAR-T
Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.
Sy Mukherjee • Aug. 25, 2026 -
Permission granted by Courtesy of Helus Pharma
How Helus’ new CEO plans to scale its psychedelic drug pipeline
Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic era?
Kelly Bilodeau • Aug. 18, 2026 -
Permission granted by Merck & Co.
Merck is pharma’s most patent-exposed company. Now it’s reinventing itself.
Keytruda made Merck an oncology powerhouse, but as the patent cliff looms, its business development leader outlines what’s next.
Meagan Parrish • Aug. 5, 2026 -
Permission granted by Telix Pharmaceuticals
How Telix landed a $2.1 billion radiopharma deal with Regeneron
Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.
Alexandra Pecci • July 30, 2026 -
Permission granted by Eli Lilly
Beyond weight loss: Lilly aims for leadership in brain science
Lilly’s neuroscience chief discusses the large pharma’s aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer’s.
Kelly Bilodeau • July 21, 2026 -
Permission granted by Rivus Pharmaceuticals
With a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark
Rivus Pharmaceuticals’ CEO Jorge Bartolome said the biotech is on track to build a “truly differentiated” cardiometabolic portfolio.
Alexandra Pecci • June 9, 2026 -
Permission granted by Bristol Myers Squibb
In Alzheimer’s, Bristol Myers sees big promise beyond amyloid
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
Jacob Bell • May 27, 2026 -
Permission granted by American Biotech Innovation Alliance
China’s biotech rise sparks new US industry alliance
The nonprofit is aiming to inspire a new moonshot effort that helps the U.S. maintain its position as a drug innovation leader.
Kelly Bilodeau • May 21, 2026 -
Permission granted by Ovid Therapeutics
Former Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech
The long-time pharma exec is on a quest with a new book and bold message for biotech leaders and U.S. lawmakers.
Meagan Parrish • May 15, 2026 -
Getty Images
How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup
Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the crowd.
Jacob Bell • March 26, 2026 -
Getty Images
VC sees early signs of a biotech market spring as long winter fades
The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.
Michael Gibney • March 17, 2026 -
Permission granted by Exact Sciences
Cancer tests are becoming more precise and guiding pharma R&D
Abbott’s major takeover of Exact Sciences showcases a rising push to leverage cancer tests in precision oncology therapy and R&D.
Michael Gibney • March 5, 2026 -
Permission granted by Ovid Therapeutics
Ovid takes another big swing in neuroscience under a new CEO
After multiple setbacks, the company is chasing a CNS target it believes has “revolutionary” potential.
Meagan Parrish • Feb. 13, 2026 -
Andrew Harnik/ via Getty Images
Politicization runs deeper than ever at FDA, risking long-term impacts
Wide-ranging shifts at the FDA have set the stage for decisions that drag the agency through the political mud, according to an economist and public policy expert.
Michael Gibney • Jan. 29, 2026 -
Permission granted by Biogen
Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth
Guy Hadari discusses how his role has changed with the introduction of new technologies, and what that means for Biogen’s future.
Michael Gibney • Dec. 19, 2025 -
Permission granted by Eli Lilly
How Lilly uses Big Pharma heft to lift up-and-coming biotechs
With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.
Michael Gibney • Dec. 9, 2025 -
Permission granted by BeOne
BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?
The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.
Michael Gibney • Dec. 4, 2025 -
Permission granted by Geron
After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing
Harout Semerjian, whose pedigree includes launching the Novartis cancer blockbuster Gleevec, is aiming to boost awareness about Geron’s Rytelo to give it momentum.
Alexandra Pecci • Nov. 12, 2025 -
Permission granted by Teva
Overcoming past mistakes, generics powerhouse Teva embraces an innovative ‘mindset change’
In the three years since a leadership change, Teva has evolved its R&D approach beyond a long history making copycat medicines.
Michael Gibney • Oct. 7, 2025 -
Getty Images
Lilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics
The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.
Michael Gibney • Sept. 23, 2025 -
Getty Images
Can new Alzheimer’s tests help clear the way for the next generation of therapies?
A tau-related blood test could offer more insight in early-disease pathology to the complicated Alzheimer’s disease space.
Michael Gibney • Sept. 9, 2025 -
Getty Images
In cell therapy, cost is a hot issue. The industry might need a cold solution.
The logistical linchpin of cryopreservation could make a challenging space more accessible.
Michael Gibney • Aug. 19, 2025 -
Permission granted by AstraZeneca
Inside AstraZeneca’s long-game strategy in lung cancer
New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.
Michael Gibney • Aug. 7, 2025
